Drugs / ABCL635
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07118891 | Jun 2025 → Feb 2027 expected | — | AbCellera Biologics Inc. | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-10 | AbCellera Biologics Inc. | Results AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile abcellera.com ↗
AbCellera (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. |
| 2026-05-11 | AbCellera Biologics Inc. | Results AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 abcellera.com ↗
ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. |
| 2025-05-14 | AbCellera Biologics Inc. | Regulatory AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause abcellera.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABCL635 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07118891 ↗ |
| Route | Subcutaneous | “administered by subcutaneous (SC) injection” NCT07118891 ↗ |